Amicogen아미코젠
092040 · KOSDAQ · ₩092040 · 아미코젠
₩915▲ ₩1 (0.11%)End-of-day · Oct 27, 2026 · End-of-day prices.
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | ₩42B | ₩174B | ₩160B | ₩144B | ₩125B |
| Cost of sales | ₩36B | ₩123B | ₩105B | ₩98B | ₩80B |
| Gross profit | ₩5.5B | ₩50B | ₩55B | ₩46B | ₩45B |
| Operating income | −₩17B | −₩7.1B | ₩2.1B | −₩4.9B | −₩4.6B |
| Net income | −₩30B | −₩51B | −₩21B | −₩46B | ₩4.7B |
| Net income to shareholders | −₩30B | −₩53B | −₩23B | −₩47B | ₩3.7B |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Total assets | ₩232B | ₩294B | ₩467B | ₩430B | ₩411B |
| Current assets | ₩38B | ₩88B | ₩156B | ₩144B | ₩124B |
| Cash and equivalents | ₩6.2B | ₩6.1B | ₩24B | ₩20B | ₩27B |
| Total liabilities | ₩136B | ₩171B | ₩248B | ₩260B | ₩178B |
| Current liabilities | ₩81B | ₩99B | ₩175B | ₩205B | ₩160B |
| Borrowings | ₩39B | ₩111B | ₩127B | ₩93B | ₩53B |
| Total equity | ₩96B | ₩123B | ₩219B | ₩170B | ₩233B |
| Shareholders' equity | ₩95B | ₩122B | ₩176B | ₩132B | ₩186B |
Cash flow
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash from operations | −₩24B | −₩13B | ₩8.6B | −₩22B | ₩8.1B |
| Capital spending | ₩3.7B | ₩48B | ₩63B | ₩46B | ₩47B |
| Free cash flow | −₩28B | −₩61B | −₩54B | −₩68B | −₩39B |
Consolidated where available. Amounts in won.
Also known as: Amicogen / 아미코젠 / 092040 / KRX:092040
Source: KRX statistical information